• Prostate and other male cancers

Eligard Generic Name & Formulations

General Description

Leuprolide acetate 7.5mg, 22.5mg, 30mg, 45mg; per inj; ext-rel susp for SC inj.

Pharmacological Class

GnRH analogue.

How Supplied

Single-use kit—1 (with sterile or sterile safety needle)


Eligard Indications


Palliative treatment of advanced prostate cancer.

Eligard Dosage and Administration


Allow product to reach room temperature before using; inject within 30mins of mixing. Use correct formulation. Rotate inj sites. 7.5mg SC once per month; or 22.5mg SC once every 3 months; or 30mg SC once every 4 months; or 45mg SC once every 6 months.


Not established.

Eligard Contraindications

Not Applicable

Eligard Boxed Warnings

Not Applicable

Eligard Warnings/Precautions


May worsen metastatic vertebral lesions and/or urinary tract obstruction; monitor closely during first few weeks. Increased risk of diabetes, MI, sudden cardiac death, stroke; monitor blood glucose, HbA1c, and for signs/symptoms of CVD during therapy. Risk of QT prolongation in patients with congenital long QT syndrome, CHF, or frequent electrolyte abnormalities. Correct and monitor electrolyte abnormalities; consider monitoring ECGs. Monitor serum testosterone, PSA periodically. Embryo-fetal toxicity. Pregnancy. Nursing mothers: not recommended.

Eligard Pharmacokinetics

See Literature

Eligard Interactions


Caution with concomitant drugs known to prolong the QT interval. May interfere with pituitary-gonadal diagnostic tests.

Eligard Adverse Reactions

Adverse Reactions

Malaise, fatigue, hot flashes/sweats, testicular atrophy, local reactions (eg, burning/stinging, pain, erythema, bruising, pruritus); transient worsening of signs/symptoms (eg, bone pain, neuropathy, hematuria, bladder outlet obstruction), spinal cord compression, hyperglycemia, decreased bone density; rare: pituitary apoplexy.

Eligard Clinical Trials

See Literature

Eligard Note

Not Applicable

Eligard Patient Counseling

See Literature